Meeting
2013 ASCO Annual Meeting
Second-line treatment of HER2+ metastatic breast cancer (MBC): Trastuzumab (T) beyond progression or lapatinib (L)? A retrospective database study.
Authors
Rinat Yerushalmi
Institute of Oncology, Davidoff Cancer Center, Beilinson Hospital, Rabin Medical Center, Petach Tiqva, Israel
Rinat Yerushalmi , Ilan Feldhamer , Sari Greenberg-Dotan , Haim Bitterman , Ariel Hammerman
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Breast Cancer - HER2/ER
Track
Breast Cancer
Sub Track
HER2+
Citation
J Clin Oncol 31, 2013 (suppl; abstr 639)
DOI
10.1200/jco.2013.31.15_suppl.639
Abstract #
639
Poster Bd #
13F
Abstract Disclosures
Similar Posters
Poster
2011 ASCO Annual Meeting
HER2 suppression with the addition of lapatinib to trastuzumab in HER2-positive metastatic breast cancer (LPT112515).
First Author: N. U. Lin
Poster
2021 ASCO Annual Meeting
The prognostic performance of PREDICT+ in patients (pts) with HER2-positive (HER2+) early-stage breast cancer (EBC).
First Author: Elisa Agostinetto
Poster
2013 ASCO Annual Meeting
Progression-free survival (PFS) as surrogate endpoint for overall survival (OS) in clinical trials of HER2-targeted agents in HER2-positive metastatic breast cancer (MBC): An individual patient data (IPD) analysis.
First Author: Stefan Michiels
Poster
2011 ASCO Annual Meeting
Ongoing clinical development of lapatinib in HER2-positive (HER2+) metastatic breast cancer (MBC): An innovative approach to recruit patients in clinical studies.
First Author: S. R. D. Johnston